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Abstract: In clinical practice, the metabolic syndrome can lead to multiple complications, including
diabetes. It remains unclear which component of the metabolic syndrome (obesity, inflammation,
hyperglycemia, or insulin resistance) has the strongest inhibitory effect on stem cells involved in beta
cell regeneration. This makes it challenging to develop effective treatment options for complications
such as diabetes. In our study, experiments were performed on male C57BL/6 mice where metabolic
disorders have been introduced experimentally by a combination of streptozotocin-treatment and
a high-fat diet. We evaluated the biological effects of Bisamide Derivative of Dicarboxylic Acid
(BDDA) and its impact on pancreatic stem cells in vivo. To assess the impact of BDDA, we applied a
combination of histological and biochemical methods along with a cytometric analysis of stem cell
and progenitor cell markers. We show that in mice with metabolic disorders, BDDA has a positive
effect on lipid and glucose metabolism. The pancreatic restoration was associated with a decrease of
the inhibitory effects of inflammation and obesity factors on pancreatic stem cells. Our data shows
that BDDA increases the number of pancreatic stem cells. Thus, BDDA could be used as a new
compound for treating complication of the metabolic syndrome such as diabetes.
Keywords: metabolic disorders; diabetes; tissue-specific stem cells; Bisamide Derivative of
Dicarboxylic Acid; regeneration
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1. Introduction
By definition of the International Association of Diabetes, metabolic syndrome (MS) is
a combination of abdominal obesity, insulin resistance, hyperglycemia, dyslipidemia, arterial
hypertension, disruption the hemostatic system, and chronic subclinical inflammation [1,2]. MS
is a widespread complex of symptoms which is pandemic in industrialized countries (e.g., in the USA,
Germany, France, New Zealand, and Australia) where it is found in every fifth adult person. The
prevalence of MS is expected to increase by 50% in the next 25 years [3,4]. A major concern is a steady
increase in the frequency of MS among adolescents and young people [5]. The main etiological factors
of MS are genetic predisposition, excessive fat intake, and hypodynamia [6].
The clinical significance of MS lies in its complications, especially in combination with other
diseases where it accelerates their development and progression [7,8]. In this context, MS can lead
to serious complications such as cardiovascular disease, type 2 diabetes, osteoarthritis, sleep apnea,
non-alcoholic steatohepatitis, respiratory problems, malignant tumors, and type 2 diabetes [9–13].
There is a linear relationship between the body mass index (BMI) and mortality from coronary heart
disease (CHD), stroke, and diabetes [14,15].
Currently, there is little progress in developing curative therapies for complications of MS.
A possible alternative to hormonal therapy of diabetic complications in patients with MS could be
a selective drug affecting endogenous tissue-specific stem and progenitor cells. In such scenario, in
addition the pharmacologically active molecule, a specific cellular target needs to be defined. Based
on the findings from our previous studies suggesting that Bisamide Derivative of Dicarboxylic Acid
(BDDA) has regenerative properties [16], we aimed to assess the efficacy of BDDA in metabolic
disorders and their complications such as diabetes in a mouse model of metabolic disorders (MD).
In addition, we evaluated the effects of BDDA on pancreatic stem and progenitor cells as potential
cellular targets of BDDA.
2. Results and Discussion
2.1. The Effect of BDDA on Serum Lipid Profile in MD
The disturbances in fat metabolism were accompanied by hyperglycemia, abnormal (glucose
tolerance test) GTT, elevated serum Gastric inhibitory polypeptide (GIP), and insulin. Overall, these
changes correspond to the clinical pattern of metabolic disorders (MD). Streptozotocin and high-fat
diet caused an increase in the concentration of triglycerides (TG) (compared with intact values of
1.38 ± 0.15 by 15%) and very low-density lipoproteins (VLDL) (compared with intact values 0.41 ± 0.08
by 38%) in the serum of male C57BL/6 mice (group 2—mice with metabolic disorders) compared to
the intact control (group 1) on d70, with an increase in the atherogenic index (by 43%) (Figure 1).
In contrast, the level of high-density lipoproteins (HDL) significantly decreased by 15% (compared
with intact values 2.41 ± 0.09). The BDDA introduction reduced the concentration of TG (by 8%), LDL
(29%) and VLDL (by 16%) in serum, the atherogenic index (by 25%) in mice of group 3 (mice with MD
treated with BDDA) on d70 compared with group 2 mice. At the same time, we observed an increase
in the level of serum HDL (by 6.5%). In addition, we studied the ratio of triglycerides to high-density
lipoproteins (TG/HDL) [17,18]. As evident in Figure 1E, the parameter was significantly higher in mice
with MD compared to the control group (1.5 fold). The BDDA treatment reduced the ratio of TG/HDL
in group with MD compared to the controls.
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Figure 1. Lipid profile measurements in the blood of male C57BL/6 mice at d70. (A) The very 
low-density lipoprotein level (Mmol/L); (B) high-density lipoprotein level (Mmol/L); (C) the level of 
triglycerides in serum (Mmol/L); (D) the atherogenic index; (E) the ratio of triglycerides to 
high-density lipoproteins (TG/HDL). Groups: Intact—a control group from intact mice, MD—mice 
with MD, MD + BDDA—mice with MD treated BDDA. *: significance of difference compared with 
intact (p < 0.05); ●: significance of difference compared with the MD group (p < 0.05). 
2.2. The Effect of BDDA on Blood Glucose, GTT, and Insulin in Blood Serum 
Simultaneous with fat metabolism disorder in mice of group 2, hyperglycemia was registered 
(the d42, d49, d56, d63, and d70) and a failure of the glucose tolerance test (d70) (Figure 2A,B). Serum 
insulin concentrations increased significantly (d70) (Figure 2C). On d70, the Caro index and 
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) were assessed (Figure 3) [19]. 
Tissue insulin sensitivity was determined by Quantitative Insulin Sensitivity Check Index (QUICKI) 
(Figure 3C) [20]. Data presented in Figure 3 that shows that tissue sensitivity to glucose changed, 
and insulin resistance developed in group 2. Introduction of BDDA reduced the levels of glucose in 
blood of mice on d56, d63, d70 and did not affect GTT in MD (Figure 2B), while it significantly 
reduced the level of serum insulin on d70 (Figure 2C). 
Figure 1. Lipid profile measurements in the blood of male C57BL/6 mice at d70. (A) The very
low-density lipoprotein level (Mmol/L); (B) high-density lipoprotein level (Mmol/L); (C) the level of
triglycerides in serum (Mmol/L); (D) the atherogenic index; (E) the ratio of triglycerides to high-density
lipoproteins (TG/HDL). Groups: Intact—a control group from intact mice, MD—mice with MD, MD +
BDDA—mice with MD treated BDDA. *: significance of difference compared with intact (p < 0.05);
: significance of difference compared with the MD group (p < 0.05).
2.2. The Effect of BDDA on Blood Glucose, GTT, and Insulin in Blood Serum
Simultaneous with fat metabolism disorder in mice of group 2, hyperglycemia was registered (the
d42, d49, d56, d63, and d70) and a failure of the glucose tolerance test (d70) (Figure 2A,B). Serum insulin
concentrations increased significantly (d70) (Figure 2C). On d70, the Caro index and Homeostasis
Model Assessment of Insulin Resistance (HOMA-IR) were assessed (Figure 3) [19]. Tissue insulin
sensitivity was determined by Quantitative Insulin Sensitivity Check Index (QUICKI) (Figure 3C) [20].
Data presented in Figure 3 that shows that tissue sensitivity to glucose changed, and insulin resistance
developed in group 2. Introduction of BDDA reduced the levels of glucose in blood of mice on d56,
d63, d70 and did not affect GTT in MD (Figure 2B), while it significantly reduced the level of serum
insulin on d70 (Figure 2C).
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Figure 2. Blood glucose level (A), glucose tolerance test (B), and insulin level in serum of mice at d70 
(C). Groups: intact—a control group from intact mice, MD—mice with MD, MD + BDDA—mice with 
MD treated BDDA. Results are presented as the mean ± SEM. *: significance of difference compared 
with intact (p < 0.05); ●: significance of difference compared with the MD group (p < 0.05). #: 
significance of difference compared with the baseline (0) (p < 0.05). 
 
Figure 3. Caro (A) indices and HOMA-IR (B), QUICKI (C), UE were measured at d70. The Caro index 
and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) were estimated using the 
following formulas: Caro = GN/IN and HOMA−IR= (IN × IG)/22.5, where IN-insulin is fasting, IU/ml; 
GN—fasting glucose, Mmol/L. Groups: intact—a control group from intact mice, MD—mice with 
MD, MD+BDDA—mice with MD treated BDDA. *: significance of difference compared with controls 
(p < 0.05); ●: significance of difference compared with the MD group (p < 0.05). 
2.3. The Effect of BDDA on Serum Cytokine Profile  
As anticipated, single administration of streptozotocin and long-term fat diet caused significant 
changes in the cytokine levels. Figure 4 shows that in group 2, the concentration of IL-4, IL-17, 
interferon-gamma (IFN-gamma), erythropoietin (EPO), and GIP in serum increased compared to 
group 1. In contrast, the levels of IL-1β, IL-1ra, IL-5, IL-23, and tumor necrosis factor-α (TNF-α) 
decreased (Figure 4). After introduction of BDDA, we observed increased serum levels of IL-1ra, 
Figure 2. Blood glucose level (A), glucose tolerance test (B), and insulin level in serum of mice at d70 (C).
Groups: intact—a control group from intact mice, MD—mice with MD, MD + BDDA—mice with MD
treated BDDA. Results are presented as the mean ± SEM. *: significance of difference compared with
intact (p < 0.05); : significance of difference compared with the MD group (p < 0.05). #: significance of
difference compared with the baseline (0) (p < 0.05).
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changes in the cytoki e levels. Figure 4 shows hat in group 2, the concentration of IL-4, IL-17,
interferon-gamma (IFN-gamma), erythropoietin (EPO), and GIP in serum increased compared to
group 1. In contrast, the levels of IL-1β, IL-1ra, IL-5, IL-23, and tumor necrosis factor-α (TNF-α)
decreased (Figure 4). After introduction of BDDA, we observe  increased serum levels of IL-1ra,
Figure 3. Caro (A) indices and HOMA-IR (B), QUICKI (C), UE were measured at d70. The Caro
index and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) were estimated using
the following formulas: Caro = GN/IN and HOMA−IR= (IN × IG)/22.5, where IN-insulin is fasting,
IU/ml; GN—fasting glucose, Mmol/L. Groups: intact—a control group from intact mice, MD—mice
with MD, MD+BDDA— ice with MD treated BDDA. *: significance of difference compared ith
controls (p < 0.05); : significance of difference compared with the MD group (p < 0.05).
2.3. The Effect of BDDA on Serum Cytokine Profile
As anticipated, single ad inis ration of streptozotocin and long-term fat diet caused significant
chang s in the cytokine levels. Figure 4 shows that in group 2, the concentration of IL-4, IL-17,
interferon-gamma (IFN-gamma), erythropoietin (EPO), and GIP in serum increased compared to group
1. In contrast, the levels of IL-1β, IL-1ra, IL-5, IL-23, and tumor necrosis factor-α (TNF-α) decreased
(Figure 4). After introduction of BDDA, we observed increased serum levels of IL-1ra, IL-4, IL-5, IL-13,
IL-23, and GLP-1 in mice within group 3 compared to animals in group 2. Moreover, the concentration
of IL-17, IFN-gamma, and EPO was reduced (Figure 4).
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2.4. The Effect of BDDA on Tissue Morphology 
Hematoxylin and eosin staining revealed pathological changes in the pancreas of mice with 
metabolic disorders on d49 and d70. Edema and hyperemia of the exocrine part of the pancreas were 
detected in addition to a small and medium-drop fat dystrophy of acinar cells, thickening and 
growth of interlobular septa, and an infiltration of islet tissue by inflammatory cells (Figure 5A,B). 
While the number of islets of Langerhans (53%) and the number of islet cells (53%) decreased in the 
group, the area of the islets of Langerhans was reduced by 52% compared group 1. In addition, the 
number of pyknotic cells increased 2.8 fold (Figure 5D). Notably, the pathological changes on d70 
were more pronounced than on d49. 
Figure 4. The level of interleukins (1beta, 4, 5, 13, 17, 23), IL-1ra, TNF-alpha, IFN-gamma, EPO, GIP
and GLP-1 in the serum of male C57BL/6 mice at d70. Groups: intact—a control group from intact mice,
MD—mice with metabolic disorders (MD), MD + BDDA—mice with MD treated BDDA. Results are
presented as the mean± SEM. *: significance of difference compared with intact (p<0.05); : significance
of difference compared with the MD group (p < 0.05).
2.4. The Effect of BDDA on Tissue Morphology
Hematoxylin and eosin staining revealed pathological changes in the pancreas of mice with
metabolic disorders on d49 and d70. Edema and hyperemia of the exocrine part of the pancreas were
detected in addition to a small and medium-drop fat dystrophy of acinar cells, thickening and growth
of interlobular septa, and an infiltration of islet tissue by inflammatory cells (Figure 5A,B). While the
number of islets of Langerhans (53%) and the number of islet cells (53%) decreased in the group, the
area of the islets of Langerhans was reduced by 52% compared group 1. In addition, the number of
pyknotic cells increased 2.8 fold (Figure 5D). Notably, the pathological changes on d70 were more
pronounced than on d49.
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magnification were taken for each experimental animal from all experimental groups. (D) Number of 
Langerhans islets, total cellularity of the Langerhans islets, percentage of pyknotic cells in 
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On d70, multipotent beta cell progenitors (CD45–TER119–c-kit–Flk-1–), oligopotent beta cells 
precursors (CD45–TER119–CD133+CD49flow), and maturing PDX1+ beta cells in the pancreas were 
studied. Metabolic disorders reduced the number of PDX1+ beta cells and multipotent beta cell 
progenitors in the pancreas of group 2 compared to group 1, while the number of oligopotent beta 
cell precursors increased significantly (Figure 6). Application of BDDA increased the numbers of 
multipotent and oligopotent beta cell precursors and PDX1+- beta cells in the pancreas of group 3 
mice compared with group 1 (Figure 6). 
Figure 5. Photo icrographs of representative pancreas sections obtained from male C57BL/6 mice
at d70. Tissues were stained with haematoxylin-eosin. (A) Sections from control group; (B) Sections
fro ice ith etabolic disorders ( ); (C) Sections fro ice ith treated ith B fro
d49-d70. Langerhans islets ere exa ined orphologically by easuring the islet area, total islet
cells and the amount of pyknotic cells. At least 10 photomicrographs of the pancreas tissue at × 400
magnification were taken for each experimental animal from all experimental groups. (D) Number of
Langerhans islets, total cellularity of the Langerhans islets, percentage of pyknotic cells in Langerhans
islets and the area Langerhans islets. Groups: intact—a control group from intact mice, MD—mice
with metabolic disorders (MD), MD+BDDA—mice with MD treated by BDDA. Results are presented
as the mean ± SEM. *: significance of difference compared with control (p < 0.05); : significance of
difference compared with the MD group (p < 0.05).
2.5. Flow Cytometric Analysis of Cells
On d70, multipotent beta cell progenitors (CD45–TER119–c-kit–Flk-1–), oligopotent beta cells
precursors (CD45–TER119–CD133+CD49flow), and maturing PDX1+ beta cells in the pancreas were
studied. Metabolic disorders reduced the number of PDX1+ beta cells and multipotent beta cell
progenitors in the pancreas of group 2 compared to group 1, while the number of oligopotent beta
cell precursors increased significantly (Figure 6). Application of BDDA increased the numbers of
multipotent and oligopotent beta cell precursors and PDX1+- beta cells in the pancreas of group 3 mice
compared with group 1 (Figure 6).
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Figure 6. Characterization of multipotent beta cell progenitors (CD45-TER119-c-kit-Flk-1-), 
oligopotent beta cell precursors (CD45-TER119-CD133+CD49flow) and PDX1+ beta cells isolated from 
pancreata of male C57BL/6 mice on d70 (A). Groups: intact—a control group from intact mice, 
MD—mice with MD, MD + BDDA mice with MD treated BDDA. Results are presented as mean ± 
SEM. *: significance of difference compared with control (p < 0.05); ●: significance of difference 
compared with the MS group (p < 0.05). Cells were analyzed by flow cytometry using antibodies 
against mouse CD45, TER119, CD133, CD49f, c-kit, Flk-1 and PDX1. The population of CD45 and 
TER119 negative cells was defined as c-kit and Flk-1 negative and positive for CD133 and CD49f at 
the same time in the two specimens (specimen 1 - subpopulation of cells with phenotype 
CD45-TER119-c-kit-Flk-1- and specimen 2 - subpopulation of cells with phenotype 
CD45-TER119-CD133+CD49flow). The PDX1 positive cells population was sorted from third specimen. 
(B) Histogram of isotype control for IgG2a (PE), (C) Phenotype and qualitative analysis of CD45 
(PerCP), TER119 (APC-Cy7) expression, (D) Histogram of PDX1 PE expression. 
2.6. Discussion 
Development of MS is associated with obesity, inflammation, and impaired tissue susceptibility 
to insulin action (insulin resistance). All these factors play a significant role in the development of 
cardiovascular diseases (arterial hypertension, coronary heart disease) and atherosclerosis. The 
effect of MS on many other organs becomes more and more obvious with the growth of MS 
problems in modern society. To date, in clinical practice, complications of MS such as type 2 diabetes 
are increasingly noted [21–23]. Several independent research groups have shown the emergence of 
insulin resistance in mice converted to a high-fat diet [24–26]. In the present study, we have shown 
that mice who received a fat diet have excessive deposition of visceral fat (data not are shown), an 
increased body mass index (BMI) (Table S1 in the Supplementary Material). Moreover, their lipid 
spectrum is disturbed: the level of "bad" cholesterol (LDL, VLDL) increases and the level of "good" 
cholesterol (HDL) decreases. However, there is no significant shift in the cytokine profile towards 
inflammatory mediators (Figure 4). On the contrary, in this model, we observed a decrease in the 
levels of inflammatory mediators in the serum (with the exception of IL-17 and IFN-gamma), and an 
increase in the levels of erythropoietin and GIP (Figure 4). 
A high concentration of free fatty acids leads to the increased production of glucose by the liver 
(gluconeogenesis) and disruption of glucose transport inside the cells [27]. According to our data, 
animals with dyslipidemia develop hyperglycemia and insulin resistance on d49 (Figures 1 and 2). 
Figure 6. Characterization of multipotent beta cell progenitors (CD45-TER119-c-kit-Flk-1-), oligopotent
beta cell precursors (CD45-TER119-CD133+CD49flow) and PDX1+ beta cells isolated from pancreata of
male C57BL/6 mice on d70 (A). Groups: intact—a control group from intact mice, MD—mice with MD,
MD + BDDA mice with MD treated BDDA. Results are presented as mean ± SEM. *: significance of
difference compared with control (p < 0.05); : significance of difference compared with the MS group
(p < 0.05). Cells were analyzed by flow cytometry using antibodies against mouse CD45, TER119, CD133,
CD49f, c-kit, Flk-1 and PDX1. The population of CD45 and TER119 negative cells was defined as c-kit
and Flk-1 negative and positive for CD133 and CD49f at the same time in the two specimens (specimen
1 - subpopulation of cells with phenotype CD45-TER119-c-kit-Flk-1- and specimen 2 - subpopulation of
cells with phenotype CD45-TER119-CD133+CD49flow). The PDX1 positive cells population was sorted
from third specimen. (B) Histogram of isotype control for IgG2a (PE), (C) Phenotype and qualitative
analysis of CD45 (PerCP), TER119 (APC-Cy7) expression, (D) Histogram of PDX1 PE expression.
2.6. Discussion
Development of MS is associated with obesity, inflammation, and impaired tissue susceptibility
to insulin action (insulin resistance). All these factors play a significant role in the development of
cardiovascular diseases (arterial hypertension, coronary heart disease) and atherosclerosis. The effect of
MS on many other organs becomes more and more obvious with the growth of MS problems in modern
society. To date, in clinical practice, complications of MS such as type 2 diabetes are increasingly
noted [21–23]. Several independent research groups have shown the emergence of insulin resistance in
mice converted to a high-fat diet [24–26]. In the present study, we have shown that mice who received
a fat diet have excessive deposition of visceral fat (data not are shown), an increased body mass index
(BMI) (Table S1 in the Supplementary Material). Moreover, their lipid spectrum is disturbed: the
level of "bad" cholesterol (LDL, VLDL) increases and the level of "good" cholesterol (HDL) decreases.
However, there is no significant shift in the cytokine profile towards inflammatory mediators (Figure 4).
On the contrary, in this model, we observed a decrease in the levels of inflammatory mediators in the
serum (with the exception of IL-17 and IFN-gamma), and an increase in the levels of erythropoietin
and GIP (Figure 4).
A high concentration of free fatty acids leads to the increased production of glucose by the liver
(gluconeogenesis) and disruption of glucose transport inside the cells [27]. According to our data,
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animals with dyslipidemia develop hyperglycemia and insulin resistance on d49 (Figures 1 and 2).
We observed a consolidation of MD in male mice on high-fat diet on d70. A degeneration of Langerhans
islands, up to necrotic changes, and a decrease in the number of islet PDX1+ beta cells were observed in
group 2 (Figure 6). Chronic hyperglycemia and dyslipidemia is known to mediate excess production of
reactive oxygen species and to an activation of caspases inhibiting insulin secretion, which eventually
leads to apoptosis of pancreatic beta cells [28].
Pancreatic stem cells are involved in the neogenesis of producing and secreting beta cells. Studying
the potential recovery of the population of beta cells in MD, we noted a significant (3 -fold) increases in
oligopotent beta cell precursors (CD45–TER119–CD133+CD49flow) in the pancreas of mice with MD
(group 2) (Figure 6). In an earlier study, we showed differentiation of oligopotent precursors into
insulin-producing and insulin-secreting beta cells in type 1 diabetes [29]. Thus, we hypothesize that
pancreatic stem cells are involved in the process of regeneration of beta cells in MD.
Several studies reported that MS and its components such as obesity, insulin resistance and
dyslipidemia are associated with systemic inflammation, a process of which is preceded by oxidative
stress with lipid peroxidation [30–33] and abnormal changes in the cytokine profile [34–36]. In contrast,
other studies did not find changes in blood levels of TNF-α, IL-6, and IL-10 and no differential
expression of the TNF-α in adipose tissue, liver, or skeletal muscle of obese animals [24–26]. Thus,
we suggest that characterization of MD should consider the ratio of mediators of inflammation and
anti-inflammation and take both serum and tissue cytokines into account.
Numerous complications of MS including diabetes are difficult to treat using conventional
monotherapies. Treatment of patients requires a wide range of drugs and, usual, their application does
not lead to the desired outcome. In our study, application of BDDA improved serum lipid metabolism
and reduced the mass of visceral fat (data not shown), caused a hypoglycemic effect and had a positive
effect on the insulin metabolism (Figures 1 and 2). In this respect, we observed a restoration of the
islet compartment. Fat dystrophy of acinar cells was less pronounced than in untreated mice with
MD (Figure 5). This positive impact of BDDA on MD and its complications in male C57BL/6 mice was
unexpected. We hypothesized that the effects of BDDA are mediated by tissue-specific stem cells. Here,
according to our flow cytometry data, the number of pancreatic stem cells and maturing PDX1+ beta
cells increases dramatically in group 3 mice (Figure 6).
Taken together, we present evidence for the efficacy of BDDA in treating the symptoms of obesity
and diabetes, as well as stimulating the regeneration of the damaged pancreas. The positive effect
of the treatment could be partially explained by a disruption of the causal relationship between
obesity and inflammation, as well as obesity, insulin resistance, and diabetes with an increase in
proliferation and differentiation of oligopotent beta cell precursors into insulin-producing beta cells as
a cellular mechanism.
3. Materials and Methods
3.1. Animals
The experiments were performed on male C57BL/6 mice obtained from the nursery of the Surgical
Bio-modeling Department of the Goldberg ED Research Institute of Pharmacology and Regenerative
Medicine (veterinary certificate available), housed under pathogen-free conditions with food and water
ad libitum. All animal experiments were carried out in accordance with the European Convention
on the protection of vertebrates used in experiments or for other scientific purposes. The study
was approved by the laboratory animal control Committee of the Goldberg ED Research Institute of
Pharmacology and Regenerative Medicine, Tomsk NRMC (IACUC Protocol No. 114062016).
3.2. Modeling of Metabolic Disorders
Experimental MD were modeled by a single subcutaneous injection of streptozotocin into the
withers (Sigma, St. Louis, MO, USA) at a dose of 200 mg/kg in 30 µl of phosphate buffer one day
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after birth and the special diet administered on postnatal days 28–70, which was enriched with heavy
saturated fats (Ssniff EF R / M with 30% Fat, Soest, Germany, ref. No. E15116-34) [37]. The introduction
of streptozotocin was taken for the d0. Mice were co-housed (5–6 mice per cage) and entrained to a
reverse 12 h light: 12 h dark cycle. During the 28 days, mice had ad libitum access to an unpurified
standard rodent chow. The 20 mice were maintained on the standard chow diet for the entire study
and served as a healthy control group. The remaining mice were given chow standard diet ad libitum
within 28 days then they had fed a high-fat diet for six weeks to induce metabolic disorders (Figure 7).
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3.3. Pharmacological Compound
The ph rmacological compound Bisamide Derivative of Dicarboxylic Acid (BDDA), chemical
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the "PHARMENTERPRISES" Ltd Mr. Nebolsin V. E. (Figure 8) [16].
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Figure 8. Structural formula of pharmacological compound Bisamide Derivative of Dicarboxylic Acid
(BDDA), chemical formular N1,N5-bis[2-(1H-imidazole-2-Il)ethyl]glutaramide.
BDDA was dissolved in sterile distilled water. BDDA was administered intragastrically daily at a
dose of 10 mg/kg on d49—d70. Control animals received the solvent in the equivalent volume.
3.4. Experimental Groups
Mice without metabolic disorders receiving saline solution formed a control group (group 1 –
control) (Table 1). Mice with metabolic disorders were divided into two experimental groups: mice
with metabolic disorders (group 2—metabolic disorder) and mice with metabolic disorders t eated
with BDDA (group 3—m tabolic disorders treated with BDDA). All the mice were sacrificed with CO2
on d70 after streptoz tocin int duction.
Table 1. Groups of animals in the experiments in vivo.
Intact Control Metabo ic Disorders Mice with Metabolic DisordersTreated with BDDA
Males group 1 (n = 20) group 2 (n = 20) group 3 (n = 20)
3.5. Blood Glucose Test, Intraperitoneal Glucose Tolerance Test (GTT)
Blood glucose levels were measured using a glucometer (Accu-Chek Performa Nano (Roche
Diagnostics GmbH, Mannheim, Germany)) on the d28, d35, d42, d49, d56, d63, and d70.
On d70 a glucose tolerance test was performed. Measurement of the initial level of glucose in
the blood of animals was performed after 12 hours of food deprivation. After that, glucose was
administered intraperitoneally (D-glucose, Sigma, St. Louis, MO, USA) at a dose of 2 g/kg. Blood
samples to study glucose level were taken 30, 60, 90, 120, 150 min after glucose administration [38].
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3.6. Parameters Connected with Glucose Homeostasis in the Serum
Glucose level in the serum was evaluated with a glucometer Accu-Chek Performa Nano (Roche
Diagnostics GmbH, Mannheim, Germany). Insulin levels in the serum were measured with the ELISA
kit (Cusabio Biotech CO., LTD, China). On d70 the Caro index and Homeostasis Model Assessment of
Insulin Resistance (HOMA-IR) were estimated using the following formulas [19]:
Caro = GN/IN and HOMA−IR= (IN × IG)/22.5,
where IN-insulin is fasting, IU/ml; GN—fasting glucose, mmol/L.
Tissue insulin sensitivity was determined by Quantitative Insulin Sensitivity Check Index
(QUICKI) [20]:
QUICKI = 1/(login + loggn)
3.7. Lipid Profile Determination
The lipid profile was determined on the d70. Blood samples were taken from each animal in tubes
without additives, kept at room temperature for 30 minutes and then centrifuged at 300g for 30 minutes.
Serum was separated and used to study lipid profile parameters. The concentration of cholesterol and
triglycerides (TG) was determined by direct enzymatic methods using BioSystems reagents (Barcelona,
Spain) in accordance with the instructions for use. Fractions of high-density lipoproteins (HDL),
low-density lipoproteins (LDL) and very low-density lipoproteins (VLDL) were precipitated with
phosphovolframate and polyvinyl sulfate respectively, and then their concentration was determined by
the level of residual cholesterol. All the results were expressed in mmol/L. Additionally, atherogenicity
index (IA) or atherogenicity coefficient (KA) were determined. TG/HDL was assessed, as previously
described in [17,18].
3.8. Enzyme-Linked Immunosorbent Assay
The concentration of insulin, IL-1ra, IL-1beta, IL- 4, 5, 13, 17, and 23, TNF-alpha, IFN-gamma, EPO,
GIP, and GLP-1 in the serum was determined by the enzyme-linked immunosorbent assay (ELISA) in
accordance with the instructions for use (Cusabio Biotech CO., LTD, China).
3.9. Morphological Assessment of the Pancreas
The morphological assessment of the pancreas was carried out on the d70. For this purpose, the
tissues were fixed in a 10% solution of neutral formalin, processed through ascending concentrations
alcohols to xylene and poured into paraffin. Dewaxed, 5 µm thick sections were stained with
hematoxylin and eosin [39,40]. Micro-preparations from each animal were examined under a light
microscope Axio Lab.A1 (Carl Zeiss, MicroImaging GmbH; Göttingen, Germany) at 100× and
400× magnifications.
Hematoxylin-eosin was performed to assess pancreas architecture and potential presence of
inflammatory cells (neutrophils, lymphocytes, and macrophages). The area of the islets of Langerhans
and the total number of cells and the number of pyknotic cells in the islets were determined on the
pancreas preparations [41,42].
In addition, the presence of inflammatory infiltrate and the state of the microvasculature were
assessed on preparations of the pancreas.
3.10. Flow cytometric Analysis
Mononuclears from pancreas were obtained as previously described methods on d70 [37].
Expression of receptors on the surface membranes of mice mononuclear cells was analyzed using
surface markers. Briefly, cell suspensions were stained with fluorophore-conjugated monoclonal
antibodies: CD45, CD49f, CD117 (c-kit), CD309 (Flk-1), TER119, and PDX1 (all Becton Dickinson, San
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Jose, CA, USA), and CD133 (Miltenyi Biotec GmbH, Germany). Appropriate isotype controls were
used. Labeled cells were thoroughly washed with phosphate buffered saline (PBS) and analyzed on
FACSCanto II (Becton Dickinson, San Jose, CA, USA) using FACS Diva software. At least 100,000
events were recorded for each condition.
3.11. Statistical Analysis
Statistical analysis was performed using SPSS statistical software (version 15.0, SPSS Inc., Chicago,
IL, USA). Data were analyzed and presented as means ± standard error of mean. A two-sided unpaired
Student t-test (for parametric data) or Mann-Whitney test (for nonparametric data) was used according
to distribution. A P value of less than 0.05 (by two-tailed testing) was considered an indicator of
statistical significance.
4. Conclusions
Overall, we show that BDDA improves the physiological functions of the pancreas from animals
with metabolic disorders. This suggests that BDDA might be a promising lead compound to create
a drug to stimulate tissue regeneration and the recovery of diminished tissue and organ function in
patients with metabolic disorders.
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